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We report on a serum autoantibody associated with cerebellar ataxia. Immunohistochemical studies of sera from
four patients referred for autoantibody testing revealed binding of high-titer (up to 1:5,000) IgG antibodies, mainly
IgG1, to the molecular layer, Purkinje cell layer, and white matter on mouse, rat, porcine, and monkey cerebellum
sections. The antibody bound to PC somata, dendrites, and axons, resulting in a binding pattern similar to that
reported for anti-Ca/anti-ARHGAP26, but did not react with recombinant ARHGAP26. Extensive control studies
were performed to rule out a broad panel of previously described paraneoplastic and non-paraneoplastic
anti-neural autoantibodies. The characteristic binding pattern as well as double staining experiments suggested inositol
1,4,5-trisphosphate receptor type 1 (ITPR1) as the target antigen. Verification of the antigen included specific neutralization
of the tissue reaction following preadsorption with ITPR1 (but not ARHGAP26) and a dot-blot assay with purified
ITPR1 protein. By contrast, anti-ARHGAP26-positive sera did not bind to ITPR1. In a parallel approach, a combination
of histoimmunoprecipitation and mass spectrometry also identified ITPR1 as the target antigen. Finally, a recombinant
cell-based immunofluorescence assay using HEK293 cells expressing ITPR1 and ARHGAP26, respectively, confirmed the
identification of ITPR1. Mutations of ITPR1 have previously been implicated in spinocerebellar ataxia with and without
cognitive decline. Our findings suggest a role of autoimmunity against ITPR1 in the pathogenesis of autoimmune
cerebellitis and extend the panel of diagnostic markers for this disease.
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type 1 (ITPR1, IP3RI, IP3R1, INSP3R1, ACV, CLA4, PPP1R94, SCA15, SCA29), Purkinje cells, Rho GTPase activating
protein 26 (ARHGAP26, GTPase regulator associated with focal adhesion kinase pp125, GRAF, GRAF1,
Oligophrenin-1-like protein, OPHN1L)Background
Autoimmune cerebellar ataxia (ACA) is an etiologically and
pathologically heterogeneous syndrome. Besides multiple
sclerosis, paraneoplastic neurological disorders are the most
common cause of ACA [1,2]. Many cases of paraneoplastic
ACA are associated with serum or cerebrospinal fluid auto-
antibodies to neuronal and/or glial antigens such as anti-Hu
[3], anti-Ri [4], anti-Yo [5], anti-CV2/CRMP5 [6,7], PCA-Tr/
anti-DNER [8], anti-Zic4 [9], anti-protein kinase C gamma
(PKCγ) [10], anti-mGluR1 [11,12], PCA2 [13], ANNA3 [14],
CARPVIII [15,16], or anti-voltage-gated calcium channels* Correspondence: sven.jarius@med.uni-heidelberg.de
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unless otherwise stated.(VGCC) [17]. In patients with non-paraneoplastic ACA,
antibodies to tissue transglutaminase [18,19], glutam-
ate receptor δ2 (GluRδ2) [20,21], and Homer-3 [22]
have been described. Some antibodies have been reported
both in paraneoplastic and in non-paraneoplastic con-
texts, such as antibodies to GABA B receptors (GABABR),
glutamate decarboxylase (GAD) [23-27], or dipeptidyl-
peptidase 6 (DPPX) [28,29].
Recently, we identified a novel Purkinje cell (PC) autoanti-
body (anti-Ca) in patients with autoimmune cerebellar ataxia
that targets the RhoGTPase-activating protein 26 (ARH-
GAP26, GRAF) [30-32]. Here, we report an autoantibody
that binds to PC somata, dendrites, and axons in a pattern
almost identical to that of anti-Ca/anti-ARHGAP26 [30-32]his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(ITPR1). The antibody was found in four patients with cere-
bellar ataxia (but was absent in >80 healthy and disease con-
trols), was present at high titers, and mainly belonged to the
IgG1 subclass.
Samples and methods
Samples
Anonymized testing of control samples as part of a study
evaluating the sensitivity and specificity of an immuno-
histochemical assay for NMO-IgG [33] using mouse, rat
and monkey cerebellum tissue sections led to the inciden-
tal identification of an anti-PC antibody in four serum
samples from three patients with a binding pattern similar
to that reported for anti-Ca [30]. The study was approved
by the institutional review board of the medical faculty of
the University of Heidelberg. The samples had originally
been sent for testing of antibodies associated with auto-
immune cerebellar ataxia. In the index case “cerebral
ataxia” was explicitly mentioned as the patient’s diagnosis,
in a second case, the diagnosis was that of “chronic
cerebellar syndrome responsive to immunotherapy”.
No additional clinical information is available due to
anonymization. A further patient (female, age 28 years
at onset) was identified by routine testing for cerebellar
antibodies. This patient had suffered from progressive
cerebellar ataxia since 2004. Symptoms included ataxia
of the upper limbs, dysarthria, and gaze disturbances.
MRI showed moderate cerebellar atrophy. Steroid treat-
ment in 2007 and ten cycles of plasma exchange treatment
in the same year had failed to halt disease progression.
However, the patient’s symptoms have not worsened since
2010, and she was still able to work full-time in an office
at last follow-up in June 2013. The patient and a relative
tested positive for BCRA1, which is associated with
increased risk of cancer, but extensive tumor screening
(including CT, PET, mammography, and breast ultra-
sound) was negative. The patient gave written informed
consent.
Immunohistochemistry (IHC)
IHC was performed on cryosections of adult mouse, rat,
and rhesus monkey cerebellum, rhesus monkey ocular bulb,
and rhesus monkey intestine tissue (Euroimmun, Luebeck,
Germany). Mouse, rat, and monkey tissue was provided
unfixed as snap-frozen sections (4 to 6 μm) and was fixed
with 10% formalin in phosphate-buffered saline (PBS) for
4 min before testing. For some experiments, 0.125% Triton
X-100 or 1% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate in PBS was applied to the sections for
4 min. Sections were then washed in PBS, blocked with 10%
goat serum or 10% donkey serum, depending on the
secondary antibodies used, and, after three washes
in chilled PBS, incubated with patient serum for 1 h orwith various commercial antibodies for up to 2 h. Binding
of human IgG, IgA, and IgM to central nervous system
(CNS) tissue was detected by use of polyclonal goat
anti-human IgG antibodies conjugated to fluorescein
isothiocyanate (FITC) (Euroimmun), Alexa Fluor® (AF)
488 (Invitrogen, Karlsruhe, Germany) or AF568 (Invitrogen),
polyclonal donkey anti-human IgG antibodies labeled with
Rhodamin Red-X (Dianova, Hamburg, Germany), and poly-
clonal goat anti-human IgM and anti-human IgA antibodies
conjugated to FITC (Euroimmun), respectively. For
evaluation of IgG subclasses, unconjugated sheep anti-
human IgG antibodies specific for IgG subclasses 1 to
4 (The Binding Site, Schwetzingen, Germany) were
substituted for the FITC-labeled goat anti-human IgG
antibody, and AF568-labeled donkey anti-sheep IgG
(Invitrogen; absorbed against human IgG) was used to
detect the subclass-specific antibodies. Binding of the
following commercial antibodies was detected using
goat anti-rabbit IgG AF568 (Invitrogen), goat anti-
mouse IgG AF568 (Invitrogen), donkey anti-chicken
IgG Rhodamin-Red X (Dianova), or donkey anti-goat
IgG AF488 (Invitrogen) as secondary antibodies, depend-
ing on the primary antibodies employed and on further
secondary antibodies used in double-labeling experiments:
rabbit anti-inositol-triphosphate receptor type I (ITPR1)
(Dianova); anti-Rho GTPase-activating protein 26 (ARH-
GAP26) (Santa Cruz, Heidelberg, Germany); goat anti-
Homer3 (Santa Cruz); rabbit anti-protein kinase C gamma
(PKCγ) (Santa Cruz); mouse anti-metabotropic glutamate
receptor 1α (mGluR1α) (BD Pharmingen, Heidelberg,
Germany); rabbit anti-glutamate receptor delta 2 (GluRδ2)
(Santa Cruz); mouse anti-glutamate receptor 3 (GluR3,
clone 3B3) (Millipore, Schwalbach, Germany); chicken anti-
glial fibrillary acidic protein (GFAP) (Encor Biotechnology,
Gainesville, FL, USA); rabbit anti-aquaporin4 (AQP4)
(Sigma Aldrich, Taufkirchen, Germany); mouse anti-
calbindin-D (Swant, Bellinzona, Switzerland). For se-
lected experiments, patient serum was incubated with
either full-length ITPR1 purified from rat cerebellum
[34] or recombinant full-length human ARHGAP26 (Abnova,
Taipei, Taiwan) overnight at 4°C prior to testing; the sera
were then centrifuged at 11,000 rpm for 10 min and the su-
pernatants incubated with brain tissue sections as described
above. Sections were then mounted using glycerol
standard immunofluorescence mounting medium con-
taining 4’,6-diamidino-2-phenylindole (DAPI) (1:1,000)
(Euroimmun) or ProLong Gold antifade reagent (Invitrogen).
Slides were analyzed on a Nikon 90i and a Nikon Ni-E fluor-
escence microscope (Nikon Imaging Center, University of
Heidelberg, Heidelberg, Germany).
Protein array
A commercially available human protein microarray
(Protoarray v5.0; Invitrogen) spotted with >9,000 human
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pression system previously successfully employed to iden-
tify ARHGAP26 as the target antigen of anti-Ca was
probed with the patient serum according to the manufac-
turer’s instructions as described [30].
Dot-blot assay
Protran BA79 nitrocellulose membranes (0.1 μm; Whatman)
were spotted with increasing dilutions (1.1.5, 1:3, 1:6, 1:12) of
full-length ITPR1 purified from rat cerebellum (0.6 μg/μL
solution; 9 μL/spot) [34] and of ARHGAP26 (0.14 μg/μL so-
lution; 10 μL/spot; Abnova) in 0.1% bovine serum albumin
(BSA). After drying, membranes were blocked with 5% BSA
in Tris-buffered saline (TBS) for 1 h at room temperature,
washed three times in TBS with 0.05% Tween (TBS-T), and
finally incubated with a 1:20 dilution of the patient serum in
0.1% BSA/TBS-T for 1 h at room temperature. A donkey
anti-human IgG antibody labeled with IRdye 700DX (Rock-
land) was used to detect bound IgG. Stripes were finally
washed in TBS and analyzed using an Odyssey™ fluorescence
scanner (Licor, Lincoln, NE, USA) and Odyssey™ 2.0.40 ap-
plication software (Licor). As controls, serum samples from
healthy donors were tested in the same run.
Histoimmunoprecipitation (Histo-IP)
Cerebellum from rat or pig was dissected and shock-
frozen in −160°C isopentane. The tissue was then cryosected
(4 μm) with a SM2000R microtome (Leica Microsystems,
Nussloch, Germany), placed on the entire surface of glass
slides, and dried. Whole slides were then incubated with pa-
tient’s serum (diluted 1:100) at 4°C for 3 h followed by three
washing steps with PBS containing 0.2% (w/v) Tween 20.
Immunocomplexes were extracted from the sections by
incubation in solubilization buffer (100 mmol/L Tris–HCl
pH 7.4, 150 mmol/L sodium chloride, 2.5 mmol/L EDTA,
0.5% (w/v) deoxycholate, 1% (w/v) Triton X-100 containing
protease inhibitors) at room temperature for 30 min.
Detached material was homogenized and centrifuged
at 16,000 × g at 4°C for 15 min. The clear supernatants
were then incubated with Protein G Dynabeads (Thermo-
Fisher Scientific, Dreieich, Germany) at 4°C overnight to
capture immunocomplexes. The beads were then washed
three times with PBS and eluted with PBS containing
5 mmol/L dithiothreitol and 1% (w/v) sodium dodecyl-
sulfate at 95°C for 10 min, followed by SDS-PAGE and
Western blot or mass spectrometry.
SDS-PAGE and Western blot
Proteins were analyzed by SDS-PAGE using the NuPAGE
system (ThermoFisher Scientific). Separated proteins were
either identified by mass-spectrometric analysis or electro-
transferred onto a nitrocellulose membrane by tank
blotting with transfer buffer (ThermoFisher Scientific) ac-
cording to the manufacturer’s instructions. The membraneswere blocked with Universal Blot Buffer plus (Euroimmun)
for 15 min and incubated with human serum or the poly-
clonal antibody against ITPR1 in Universal Blot Buffer plus
for 3 h, followed by three washing steps with Universal Blot
Buffer (Euroimmun), a second incubation for 30 min with
anti-rabbit IgG-AP (Sigma-Aldrich), three washing steps,
and staining with NBT/BCIP substrate (Euroimmun).
Mass spectrometry
Mass spectrometry sample preparation was performed
as reported by Koy et al. [35]. Unless otherwise indi-
cated, hardware, software, MALDI targets, peptide stan-
dards, and matrix reagents were obtained from Bruker
Daltonics, Bremen, Germany. Briefly, samples were re-
duced with dithiothreitol and carbamidomethylated with
iodoacetamide prior to SDS-PAGE. Proteins were visual-
ized with Coomassie Brilliant Blue G-250 and visible
protein bands were excised and destained. After tryptic di-
gest, peptides were extracted and spotted with α-cyano-4-
hydroxycinnamic acid onto a MTP AnchorChip™ 384 TF
target. MALDI-TOF/TOF measurements were performed
with an Autoflex III smartbeam TOF/TOF200 System
using flexControl 3.0 software. MS spectra for peptide
mass fingerprinting (PMF) were recorded in positive ion
reflector mode with 500 shots and in a mass range
from 700 Da to 4,000 Da. Spectra were calibrated exter-
nally with the commercially available Peptide Calibration
Standard II, processed with flexAnalysis 3.0, and peak lists
were analyzed with BioTools 3.2. The Mascot search en-
gine Mascot Server 2.3 (Matrix Science, London, UK) was
used for protein identification by searching against the
NCBI database limited to Mammalia. Search parameters
were as follows: mass tolerance was set to 80 ppm, one
missed cleavage site was accepted, and carbamidomethyla-
tion of cysteine residues as well as oxidation of methio-
nine residues were set as fixed and variable modifications,
respectively. To evaluate the protein hits, a significance
threshold of P <0.05 was chosen. For further confirmation
of the PMF hits, two peptides of each identified protein
were selected for MS/MS measurements using the WARP
feedback mechanism of BioTools. Parent and fragment
masses were recorded with 400 and 1,000 shots, respect-
ively. Spectra were processed and analyzed as described
above with a fragment mass tolerance of 0.7 Da.
Cloning and expression of ITPR1 in HEK293
The coding DNA for human ITPR1 (Genbank # BC172648,
Source BioScience LifeSciences, Nottingham, UK) was
transferred into the expression vector pTriEx-1 (Merck).
The receptor was expressed in the human cell line
HEK293 after ExGen500-mediated transfection (Ther-
moFisher Scientific) according to the manufacturer’s
instructions. For the preparation of substrates for a re-
combinant cell-based indirect immunofluorescence assay
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transfected, and allowed to express the recombinant pro-
teins for 48 h. Cover glasses were washed with PBS, fixed
with acetone for 10 min at room temperature, air-dried,
cut into millimeter-sized fragments (biochips), and used
as substrates in RC-IFA. Alternatively, cells were trans-
fected in standard T-flasks and the cells were harvested
after 5 days. The cell suspension was centrifuged at
1,500 × g, 4°C for 20 min and the resulting sediment
was extracted with solubilization buffer (see above). The
extracts were stored in aliquots at −80°C until further use.
Results
Detection of a new Purkinje cell reactivity
Immunohistochemistry on formalin-fixed frozen adult
mouse, rat, and monkey tissue sections demonstrated
strong reactivity of serum to structures in the molecular
layer (ML), the Purkinje cell layer (PCL), and the white
matter (WM) of the cerebellum (Figure 1), similar toFigure 1 Binding of patient IgG to the Purkinje cell (PC) dendrites (PC
(PCL), and to the PC axons (PCA) in the white matter (WM) on murine
similar to that observed with anti-Ca/ARHGAP26 (see reference [30]). Note
that the PCD (B and C) and the PCA (D and E) staining patterns can differ
be detectable on all sections. GL, Granular cell layer.that of anti-Ca/ARHGAP26 [30-32]. More detailed ana-
lysis at higher magnification revealed binding of IgG to
somata, dendritic trunks, dendritic branches, and possibly
dendritic spines of PCs, as previously described for anti-
ARHGAP26 (anti-Ca). In addition, axons in the WM were
stained by the patients’ serum. Double labeling with anti-
GFAP and anti-AQP4 revealed no binding of the patient
antibody to astrocytes in the WM and the granular layer
(GL), or to Bergman glial cells in the PCL and ML (not
shown). As anti-Ca/ARHGAP26, the antibodies spared in-
terneurons, such as stellate cells, basket cells, and Golgi
cells, as well as granular cells. The antibody stained PC
somata and PC axons more intensely than anti-Ca/ARH-
GAP26-positive sera in a direct comparison, equaling the
fluorescence intensity of the molecular layer. Interestingly,
using primate enteric tissue sections, no binding to the
plexus myentericus was observed, but there was strong
staining of both the circular and the longitudinal tunica
muscularis as well as of the muscularis propria and ofD) in the molecular layer (ML), to the PC somata in the PC layer
cerebellum tissue sections. The observed staining pattern (A) is
that PC nuclei, interneurons, and granular cells are spared. Also note
significantly depending on sectional planes. Axonal staining may not
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linear fluorescence adjacent to the epithelium of the intes-
tinal villi. No such fluorescence was detected with anti-
ARHGAP26-positive sera, which stained the myenteric
plexus but not the muscle layers. Of note, enteric tissue
sections have been previously used to differentiate between
anti-Hu and anti-Ri antibodies, two anti-neuronal anti-
bodies that are otherwise difficult to distinguish. We de-
cided to refer to the specific staining pattern described
here as anti-Sj throughout the manuscript, following a
widely accepted convention to name newly described anti-
bodies with reference to the index sample’s initials or code.
In a direct comparison of mouse, rat, and monkey cere-
bellum tissue sections, incubated simultaneously with the
patients’ sera within the same well, mouse tissue was
found to produce a slightly more clear and distinct sig-
nal than rat and primate tissue (mouse > rat > primate).
The immunoglobulin class and IgG subclass reper-
toire of the PC antibodies was analyzed by IHC in two
patients—no material was left for analysis in the re-
mainder—and revealed mainly IgG1 antibodies in both
cases (Figure 2). Very weak IgG2 or IgG3 staining was
observed in both patients and in one patient, respect-
ively. In both patients, no anti-PC antibodies of the IgM
or IgA class were detectable.
Cerebrospinal fluid was available from a single serum-
positive patient and showed PC-specific staining identi-
cal to that observed with the patient’s serum sample.Figure 2 Analysis of the IgG subclasses of anti-Sj in the index
patient. Subclass analysis revealed mainly IgG1 antibodies (depicted
in red) with very few IgG2 and no IgG3 or IgG4 antibodies (not shown);
no PC-specific antibodies to IgA or IgM were detectable (not shown).
IgG1 was also the main anti-Sj IgG subclass in a second patient
(not shown).No evidence of previously described CNS autoantibodies
All reference sera were negative for anti-ARHGAP26 in
a previously described dot-blot assay [30-32]. The index
serum was, in addition, tested for anti-ARHGAP26 in
the same commercial protein microarray originally used
to identify ARHGAP26 as the target antigen of anti-Ca
[30], which employs full-length human ARHGAP26 from
a second, independent manufacturer (Invitrogen), but was
also negative in this assay (median fluorescence units [FU]
at 635 nm, 38; median fluorescence of all proteins, 158,
compared to 55,323 and 181, respectively, in the anti-Ca/
ARHGAP26 index case [30]). No evidence was found for
anti-Hu, anti-Ri, anti-Yo, anti-Ma, anti-Ta, anti-CV2/
CRMP5, anti-amphiphysin, ANNA-3 [14], PCA-2 [13],
or anti-Tr/DNER [8,36,37]. Antibodies to Homer-3 [22],
PKCγ [10], mGluR1[12,38], and GluRδ2 [20,21], which
have been described in occasional patients with cerebellar
ataxia and are known to bind to PC somata and/or den-
drites, were ruled out by double-labeling experiments
employing mouse, rat, and monkey cerebellum tissue sec-
tions as well as by Western blot analysis (not shown).
Anti-CARPVIII [15,16] and Homer3 were excluded by
RC-IFA (Euroimmun) and based on Western blotting.
Antibodies to aquaporin-4, myelin oligodendrocyte glyco-
protein, NMDA receptor, AMPA receptors 1 and 2, GABA
B receptor, DPPX, LGI1, CASPR2, and Homer-3 were
ruled out by IFA on cerebellum and hippocampus tissue
sections and by RC-IFA using HEK293 expressing these
antigens (Euroimmun). PKCγ, Zic4, GAD, amphiphysin,
and GluRδ2 were included also in the protein microarray
incubated with the index patient’s serum, but were not rec-
ognized by the patient’s IgG.
Identification of ITPR1 as the target antigen by IFA and
dot blot
The staining pattern observed with the patients’ serum
highly resembled the pattern observed by us in a previ-
ous study with a commercial antibody to the inositol
1,4,5-trisphosphate receptor, type 1 (ITPR1) [30]. Double
staining of cerebellum sections with that commercial
antibody, which is used as a well-established marker of
PCs in our laboratory, showed a perfect overlay with the
staining pattern found with the patient antibody in the
ML, PCL and WM (Figure 3). By contrast, sera positive
for anti-ARHGAP26 had shown only partial overlay
using the same commercial anti-ITRP1 antibody (see
Figure 13 in ref. [30]). In addition, an overlay between
the patients’ IgG and the commercial anti-ITPR1 anti-
body was also observed on other tissue sections, in-
cluding intestine (Figure 4) and bulbus oculi sections
(Figure 5), corroborating ITPR1 as the target antigen.
In line with these findings, IgG from the patients’ sera
but not from healthy controls bound to ITPR1 purified
from rat cerebellum in a dot-blot assay (Figure 6).
Figure 3 Perfect overlay of the binding pattern observed with patient IgG and that observed with a commercial antibody to ITPR1, a
well-established specific marker of Purkinje cells (PCs). Anti-ITPR1 reactivity is depicted in red (Alexa Fluor® 568), the patient antibody in green
(Alexa Fluor® 488), and yellow indicates overlay of the two antibodies. Nuclei are shown in blue (DAPI).
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competitive IHC
Preadsorption of the patient sera with rat ITPR1 protein
resulted in complete loss of binding to cerebellum tissue
sections (Figure 7); by contrast, preadsorption with ARH-
GAP26 did not. Interestingly, only preadsorption with full-
length ITPR1 resulted in loss of PC staining, not pread-
sorption with a partial recombinant protein (2470 a.a. to
2577 a.a.; Abnova, Taiwan), indicating that the target
epitope either depends on protein conformation or glycosy-
lation or is located outside the residues 2470 a.a. to 2577 a.a.
Parallel identification of ITPR1 as the target antigen by
MALDI-TOF
Histoimmunoprecipitates from either rat or porcine cerebe-
llum contained high amounts of IgG when one of the refer-
ence sera was used, whereas they were generally low after
incubation of sera from healthy controls. Next to the im-
munoglobulins, the immunoprecipitated PC antibody-
positive reference serum showed a protein band corre-
sponding to a molecular mass of approximately 300 kDa
in SDS-PAGE stained with colloidal Coomassie (Figure 8).The band was absent in the control samples. The
proteins precipitating from rat and porcine cerebe-
llum were identified as ITPR1 from the corresponding
organisms by mass-spectrometric analysis. Western
blot analysis with the polyclonal rabbit anti-ITPR1
antibody showed a strong reaction at 300 kDa of the
immunoprecipitate obtained with the patient serum,
while there were no reactions with fractions obtained
with control sera. When used for double staining in
IFA, the polyclonal anti-ITPR1 antibody produced an
overlay with the reference serum used in the MALDI-
TOF experiments.
Confirmation of ITPR1 as the target antigen by
recombinant cell-based IFA
As further confirmation of correct antigen identification, the
PC antibody-positive sera and controls were then analyzed
by an RC-IFA using HEK293 expressing murine ITPR1 and
mock-transfected HEK293 (Figure 9, upper panel). All refer-
ence sera but none of the controls reacted with the ITPR1-
expressing cells (Figure 9, middle panel). In contrast, mock
transfection did not result in any antibody binding (Figure 9,
Figure 4 Double labeling of primate intestine sections with patient serum and with commercial antibodies to anti-ITPR1 or ARHGAP26,
respectively. The anti-Sj index serum and the commercial antibody to ITPR1 (A) stained both the stratum circulare (SC) and the stratum
longitudinale (SL) of the tunica muscularis as well as the muscularis mucosae (MM) and structures adjacent to the enteric villi (V), with a perfect
overlay, but spared the plexus myentericus Auerbach (MP), which is located between SC and SL. Conversely, the anti-Ca index serum [30] and the
commercial antibody to ARHGAP26 (B) both stained the MP (and the plexus submucosus Meissner; not shown) but spared the enteric muscle
cells. Anti-ITPR1 or anti-ARHGAP26 reactivity is depicted in red (Alexa Fluor® 568), the patient antibody in green (Alexa Fluor® 488), and
yellow indicates overlay of the two antibodies. Nuclei are shown in blue (DAPI).
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target and ITPR1 was further demonstrated by the dose-
dependent competitive abolition of antibody binding to PCs
by HEK293 lysates containing ITPR1 (Figure 7E). Antibody
binding was unaffected when comparable lysates from
mock-transfected HEK293 were used (Figure 7F).
Specificity of anti-ITPR1 autoantibodies
Sera from 30 patients with various neural autoantibodies
(anti-NMDAR, anti-Hu, anti-Yo, anti-Ri, anti-aquaporin
4, anti-LGI1, anti-CASPR2) and from 50 healthy con-
trols were analyzed in the RC-IFA in parallel to the sam-
ples of the PC antibody-positive patients. None of theFigure 5 Double labeling of primate bulbus oculi tissue sections with p
of the index patient’s IgG and a commercial antibody to ITPR1 was also ob
(A: ciliary muscle, B: retina with rod and cone processes), confirming the sp
depicted in red (Alexa Fluor® 568), the patient antibody in green (Alexa Flu
shown in blue (DAPI).sera produced an immunofluorescence pattern similar to
that of the index sera on the recombinant substrate. None
of the four available anti-Ca/anti-ARHGAP26-positive
sera [30-32] bound to full-length rat ITPR1 in the dot-
blot assay or to full-length human ITPR1 in the RC-IFA.
Discussion
Here we report on serum autoantibodies with high specifi-
city to PCs. Using a broad panel of immunological
methods, including immunohistochemistry and histoim-
munoprecipitation combined with mass spectrometry,
protein-based immunoassays, and RC-IFA, we identified
ITPR1 as the target antigen of this serum reactivity. ITPR1atient serum and a commercial antibody to anti-ITPR1. An overlay
served outside the CNS and the intestine, e.g., in the eye bulb
ecificity of the patient antibody for ITPR1. Anti-ITPR1 reactivity is
or® 488), and yellow indicates overlay of the two antibodies. Nuclei are
Figure 6 Results from an dot-blot assay employing purified ITPR1 and ARHGAP26 as test substrates. IgG from the patients’ serum bound
to full-length ITPR1 but not to human full-length ARHGAP26; contrarywise, anti-Ca-positive control sera bound to ARHGAP26 but not to ITPR1
(upper panel). The minimum amount of ITPR1 that resulted in a significant staining intensity was 0.45 μg/μL (middle panel). Healthy control
sera bound neither to ITPR1 nor to ARHGAP26 (middle and lower panel).
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lular calcium signaling following stimulation by inositol
1,4,5-trisphosphate [39,40].
Our findings expand the panel of diagnostic serum
markers of autoimmune cerebellar ataxia. Due to
the sometimes very similar tissue stainings, it is im
portant to differentiate anti-ITPR1 from other PC
autoantibodies in general, and particularly from anti-
ARHGAP26 antibodies [30-32], by means of a spe-
cific assay.
Whether anti-ITPR1 is pathogenic is unknown. On the
one hand, there is some indirect evidence for a potentialpathogenic role: First, the antibody is highly specific for
PCs, a cell type expressed exclusively in the cerebellum,
and the patients presented with cerebellar ataxia. Second,
the antibody belonged to the IgG1 subclass, which is
known to be a strong complement activator, suggesting
that it may act on PCs via complement-dependent
mechanisms, which are well-established features in other
autoantibody-associated disorders [41,42], though other
direct effects such as antibody-dependent cell-mediated
cytotoxicity or induction of apoptosis might also play a
role. Third, the antibody was present at high titers (1:5,000,
1:3,200, 1:3,200, 1:1,000, according to IHC). Moreover,
Figure 7 Results from preadsorption experiments. Preadsorption of the patient serum with purified rat ITPR1 or an extract of HEK293 cells
expressing murine ITPR1 resulted in complete loss of binding to cerebellar tissue sections in an indirect immunofluorescence assay (A, B, E). In
contrast, binding of anti-Ca/ARHGAP26-positive sera was not affected by preadsorption with ITPR1 (C, D). Preadsorption of anti-ITPR1-positive
patient serum with full-length human ARHGAP26 (not shown) or with an extract of mock-transfected HEK293 (F) did not affect binding to PCs.
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nocerebellar ataxia 15 (SCA15) and 29 (SCA29), drawing a
link between malfunction of ITPR1 and disease [43,44].
SCA29 is an autosomal dominant disorder with onset in
infancy characterized by a very slowly progressive or non-
progressive gait and limb ataxia associated with cerebellar
atrophy on brain imaging. Heterozygous mutations in the
ITPR1 gene cause SCA15 with later onset. ITPR1-deficient
mice born alive also show severe ataxia [45]. On the other
hand, ITPR1 is primarily an intracellular antigen located in
membranes encompassing the endoplasmatic or sarcoplas-
matic (in muscle cells) reticulum, though surface localizationhas also been reported under certain circumstances [46-50].
Many authors believe that intracellular antigens are
not accessible to antibodies in vivo. In fact, most
neurological autoantibodies of proven pathogenic im-
pact, such as antibodies to AQP4 in neuromyelitis
optica [42,51-53], acetylcholine receptor in myasthe-
nia gravis, VGCC in Lambert-Eaton syndrome [54],
and mGluR1 in paraneoplastic cerebellar degeneration
[11] target superstitial proteins of the plasma membrane.
Moreover, passive transfer of antibodies to nuclear anti-
gens such as anti-Yo [55-57] have not produced clinical
disease in animal studies. Instead, T cell-mediated immune
Figure 8 Histoimmunoprecipitation with a reference patient
serum revealed a band at around 300 kDa (arrow).
Figure 9 Confirmation of ITPR1 as the target antigen by a
recombinant cell-based indirect immunofluorescence assay
employing HEK293 cells transfected with full-length human
ITPR1 and mock-transfected HEK293 cells as control substrates.
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companying antibody have been proposed to play a role in
those disorders [58-61]. It is therefore possible that the
antibody has diagnostic but no pathogenic impact, similar
to the situation in many paraneoplastic neurological
syndromes.
Autoantibody-associated cerebellar ataxia is fre-
quently of paraneoplastic nature [1,2]. However, no
data on most patients’ tumor status were available in
this study. It will be of utmost importance to carefully
examine future, prospectively identified patients with
anti-ITPR1 antibodies for associated tumors. Of note,
paraneoplastic antibodies and the associated syn-
dromes can precede tumor diagnosis by several years.In a large study on patients with anti-Yo antibodies,
the most common paraneoplastic serum reactivity as-
sociated with autoimmune cerebellar ataxia, the neuro-
logic syndrome preceded the diagnosis of cancer by up
to 15 months and in many cases led to that diagnosis
[5]. This will make it crucial to follow-up future pa-
tients for at least 2 years. Of note, non-paraneoplastic
ACA have been described as well, including ACA asso-
ciated with antibodies to glutamate decarboxylase
[23,24], tissue transglutaminase [18], GluRδ2 [20,21], and
Homer-3 [22]. Anti-Ca/ARHGAP26-associated ACA has
been reported both in a paraneoplastic context and in
patients with no known tumor at the time of anti-
ARHGAP26 testing [30-32].
Jarius et al. Journal of Neuroinflammation  (2014) 11:206 Page 11 of 12We have so far identified four patients with ACA and
anti-ARHGAP26 [30-32] and four with anti-ITPR1. Inter-
estingly, several further samples sent to our laboratories
with a diagnosis of ACA showed a staining pattern
similar to that observed with anti-ARHGAP26 and anti-
ITPR1, i.e., marked staining of the PC somata, the
dendrites, and, partly, the axons, but did not react with
either ARHGAP26 or ITPR1. Whether these sera contain
antibodies other than anti-ARHGAP26 and anti-ITPR1,
e.g., anti-CARPVIII or other novel autoantibodies, is
currently under investigation.Conclusions
We describe a new autoantibody to PC somata, den-
drites, and axons associated with cerebellar ataxia. The
antibody targets ITPR1 and mainly belongs to the IgG1
subclass. Our findings indicate a possible role of auto-
immunity to ITPR1 in the pathogenesis of autoimmune
encephalitis and expand the panel of diagnostic markers
for this condition.
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